Neuronetics, Inc.

STIM ·Healthcare, Medical Devices, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-39.0M $-43.7M $-30.2M $-37.2M $-31.2M $-27.5M $-29.0M $-24.1M
Depreciation & Amortization $3.5M $2.1M $2.0M $1.6M $1.1M $941.0K $1.1M $882.0K
Depreciation
Amortization $1.5M $100.0K
Stock-Based Compensation $6.8M $5.6M $7.3M $8.7M $7.9M $4.4M $3.4M $1.7M
Net Cash from Operating Activities $-20.4M $-31.0M $-32.0M $-30.7M $-28.0M $-28.4M $-30.5M $-20.6M
Investing Activities
Capital Expenditures $801.0K $1.5M $2.4M $3.3M $2.4M $730.0K $813.0K $1.0M
Business Acquisitions $2.6M
Net Cash from Investing Activities $-801.0K $-2.4M $-1.3M $6.7M $-9.8M $-730.0K $-813.0K $-1.0M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $35.9M $-6.8M $22.7M $207.0K $83.0M $2.4M $2.4M $97.0M
Net Change in Cash
Free Cash Flow $-21.2M $-32.5M $-34.4M $-34.0M $-30.3M $-29.1M $-31.3M $-21.6M
← Newer Page 1 of 2 Older →